Maintenance of genomic stability requires accurate DNA replication. Eukaryotic cells achieve this by licensing the replication origins through recruiting the licensing factors to the origins to initiate replication and subsequently by 26S proteasome-mediated degradation of the licensing actors to prevent DNA re-replication. Eukaryotes must also maintain multiple copies of an extranuclear genome, the mitochondrial DNA (mtDNA), but the underlying mechanism for maintenance of mtDNA copy number remains a mystery. The current proposal is aimed at understanding the molecular mechanism of mtDNA replication licensing and is built on our recent discovery of HslVU protease as an essential regulator of mtDNA replication in Trypanosoma brucei, a protozoan parasite that contains an unusual mtDNA network, known as the kinetoplast DNA (kDNA). This protease is the first known regulator of kDNA replication and first bacterial-like HslVU protease identified in a eukaryote, but how it exerts its function is poorly understood, mainly because its regulatory proteins are not identified. Through tandem affinity purification, we identified two novel mitochondrial proteins that associate with TbHslVU in vivo, and we propose in this application to examine their potential roles in regulating TbHslVU as well as their potential involvement in kDNA replication. We hypothesize that the two novel proteins, named VUP1 and VUP2 for TbHslVU Partner 1 and 2, function as regulators of TbHslVU. They could either activate or inhibit the activity of TbHslVU or regulate the assembly of TbHslVU complex or mediate substrate recognition. The identification of regulatory proteins of TbHslVU suggests an additional level of control over the replication of kDNA and the complexity of the regulatory scheme of kDNA replication in trypanosomes. Most importantly, since no homologs of TbHslVU and its partners, VUP1 and VUP2, are found in humans, they are potential drug targets for anti-trypanosomiasis chemotherapy.
Human African Trypanosomiasis, also known as sleeping sickness, is a vector-borne parasitic disease. Current World Health Organization (WHO) estimates that around sixty million people in thirty-six sub-Saharan African countries are at risk of infection and 300,000 to 500,000 people are infected each year. Since drugs to cure the disease are few and often toxic to humans, further understanding of the parasite and drug development are urgently needed. Trypanosomes possess a unique mitochondrial DNA complex, kinetoplast DNA (kDNA), whose replication is under tight control and is essential for trypanosome survival. The proposed studies in this application will explore the mechanism of kDNA replication licensing by identifying and characterizing two novel proteins, VUP1 and VUP2, both of which are regulators of a novel mitochondrial protease, TbHslVU. TbHslVU is a structural equivalent of the eukaryotic 26S proteasome complex and does not have a homolog in humans. Therefore TbHslVU and its regulatory proteins are potential drug targets for anti-trypanosomiasis chemotherapy.
|Zhou, Qing; Hu, Huiqing; Li, Ziyin (2014) New insights into the molecular mechanisms of mitosis and cytokinesis in trypanosomes. Int Rev Cell Mol Biol 308:127-66|
|Han, Xianxian; Li, Ziyin (2014) Comparative analysis of chromosome segregation in human, yeasts and trypanosome. Front Biol (Beijing) 9:472-480|
|Li, Ziyin (2012) Regulation of the cell division cycle in Trypanosoma brucei. Eukaryot Cell 11:1180-90|